TrialsgrambetaRCTs are beautiful

ESC Congress 2026

The congress is over: each trial shows its result here once it is in the register.

Dates
28–31 August 2026
Place
Munich · Messe München
Status
Finished
Times
Venue time · BerlinProgramme days · Munich

Hot Line

Presentations
58
With a result
58
In the register
0
Result to follow
0

Friday 28 August

2026 ESC Guidelines and Document overview

08:15-09:45 CESTMain Auditorium (Hall B3)Session programme

Hot Line 1

11:00-12:18 CESTMain Auditorium (Hall B3)Session programme

  • 11:00CESTCARDIO-TTRansformCoreCongress resultIn 1,432 patients with transthyretin amyloid cardiomyopathy, eplontersen did not reduce cardiovascular death or recurrent cardiovascular events at 140 weeks compared with placebo.IRR 0.8995% CI 0.73-1.09
  • 11:15CESTSINGLE-AFCongress resultIn 1,803 patients with atrial fibrillation at intermediate stroke risk, a direct oral anticoagulant reduced the net composite of stroke, embolism, major bleeding and death at 2 years compared with no anticoagulation.HR 0.3195% CI 0.10-0.94
  • 11:30CESTPOET-IICongress resultIn 508 patients with left-sided infective endocarditis, a tailored 2–4-week antibiotic course was non-inferior to the standard 4–6-week course for death, unplanned cardiac surgery, relapse or embolisation at 6 months.8.2% vs 10.7%
  • 11:45CESTACACIA-HCMCongress resultIn 517 patients with symptomatic non-obstructive hypertrophic cardiomyopathy, aficamten improved KCCQ clinical summary score and peak oxygen uptake at 36 weeks compared with placebo.
  • 12:03CESTCMR GUIDECongress resultIn 353 patients with LVEF 36–50 % and scar on cardiac MRI, a primary-prevention ICD did not reduce sudden cardiac death or haemodynamically significant ventricular arrhythmia compared with an implantable loop recorder.HR 0.7695% CI 0.37-1.58

2026 ESC Guidelines for the Management of Heart Failure

13:45-15:00 CESTMain Auditorium (Hall B3)Session programme

Saturday 29 August

Hot Line 2

08:15-09:45 CESTMain Auditorium (Hall B3)Session programme

  • 08:15CESTSTAREECoreCongress resultIn 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg improved one of two co-primary outcomes disability-free survival and major cardiovascular events compared with placebo.HR 0.7095% CI 0.61-0.82
  • 08:30CESTAMUNDSENCongress resultIn 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.OR 5.5495% CI 4.50-6.82
  • 08:45CESTTRANQUILITYCongress resultIn 143 patients with chronic kidney disease and raised hs-CRP, pacibekitug, an IL-6 antibody reduced hs-CRP through day 90 compared with placebo.
  • 09:00CESTREACTCongress resultIn 16,808 adults aged 18–70 years without known cardiovascular disease, whole-body imaging for atherosclerosis was studied for the age- and sex-specific prevalence of silent atherosclerosis.
  • 09:15CESTENRICH-AFCongress resultIn 948 patients with atrial fibrillation and a previous intracranial haemorrhage, edoxaban did not reduce stroke or systemic embolism, and major haemorrhage compared with no anticoagulation.HR 0.8895% CI 0.61-1.26
  • 09:30CESTDAN-RSVCongress resultIn 511,535 adults aged 18 years or over in Denmark and Galicia, a single dose of RSVpreF vaccine reduced hospitalisation for RSV-related respiratory disease compared with no vaccine.

Hot Line 3

11:00-12:15 CESTMain Auditorium (Hall B3)Session programme

  • 11:00CESTLIBREXIA ACSCongress resultIn 14,194 patients with a recent acute coronary syndrome, milvexian added to antiplatelet therapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with placebo.HR 1.0595% CI 0.91-1.21
  • 11:15CESTPREMIUMCongress resultIn 2,216 patients with STEMI undergoing primary PCI, aspirin-free prasugrel monotherapy was not non-inferior to 12 months of dual antiplatelet therapy for death, myocardial infarction or stroke at 12 months.HR 1.3495% CI 1.02-1.75
  • 11:30CESTSWITCH SWEDEHEARTCongress resultIn 17,095 patients with an acute coronary syndrome, prasugrel as the default P2Y12 inhibitor did not reduce death, myocardial infarction or stroke at 1 year compared with ticagrelor.OR 0.9095% CI 0.77-1.06
  • 11:45CESTA-CLOSECongress resultIn 3,203 high-risk patients after 12 months of DAPT following PCI, clopidogrel monotherapy was non-inferior to extended dual antiplatelet therapy for net adverse clinical events at 24 months.5.0% vs 5.1%
  • 12:00CESTEPIDAURUSCongress resultIn 602 patients with atrial fibrillation and ACS after PCI, one month of a potent P2Y12 inhibitor plus a NOAC did not reduce major ischaemic events at 6 weeks compared with clopidogrel plus a NOAC.HR 3.5495% CI 1.15-10.85

2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease

13:45-15:00 CESTMain Auditorium (Hall B3)Session programme

Hot Line 4

16:15-17:15 CESTMain Auditorium (Hall B3)Session programme

  • 16:15CESTPRESC1SE-MICongress resultIn 67,624 emergency presentations with suspected myocardial infarction, the ESC 0/1-hour troponin algorithm was non-inferior to the 0/3-hour algorithm for death or type 1 myocardial infarction at 30 days, and length of stay.OR 0.9395% CI 0.77-1.13
  • 16:25CEST0/1-hour IPDMACongress resultIn patients with suspected myocardial infarction in pooled pathway studies, the ESC 0/1-hour troponin algorithm did not improve diagnostic safety and efficacy compared with standard-care pathways.
  • 16:45CESTAIR-STEMICongress resultIn 1,823 patients with STEMI and multivessel disease, angiography-derived FFR-guided non-culprit PCI reduced death, stroke, reinfarction or ischaemia-driven revascularisation compared with angiography-guided PCI.HR 0.6295% CI 0.47-0.83
  • 17:00CESTTARGET-CTCACongress resultIn 3,170 patients with suspected ACS, infarction ruled out and an intermediate troponin, outpatient CT coronary angiography did not reduce myocardial infarction or cardiac death compared with standard care.HR 0.9595% CI 0.73-1.23

Hot Line 5

17:30-18:35 CESTMain Auditorium (Hall B3)Session programme

  • 17:30CESTEMAIL-HFCongress resultIn 5,996 patients with heart failure not on an SGLT2 inhibitor, a digital letter inviting specialist review increased initiation of an SGLT2 inhibitor within 6 months compared with usual care.18.6% vs 8.2%
  • 17:45CESTRemote Exercise SWEDEHEARTCongress resultIn 3,112 patients after myocardial infarction referred to cardiac rehabilitation, a choice of video-delivered remote exercise did not increase the number of supervised sessions attended compared with centre-based exercise only.13.8% vs 13.6%
  • 18:00CESTADHERE-ASCVDCongress resultIn 20,604 statin-non-adherent patients with cardiovascular disease or diabetes, adaptive digital outreach was compared with usual care on a statin refill within 14 days.RR 1.295% CI 1.1-1.3
  • 18:15CESTVIRTUESCongress resultIn 1,963 patients with an ICD or pacemaker, remote-only device management via an e-health platform was non-inferior to scheduled in-clinic follow-up for major adverse cardiac events at 18 months.

Sunday 30 August

Hot Line 6

08:15-09:50 CESTMain Auditorium (Hall B3)Session programme

  • 08:15CESTH-HeFTCongress resultIn 592 patients with HFrEF on guideline-directed therapy, hydralazine–isosorbide dinitrate did not reduce death or worsening heart failure compared with placebo.HR 0.9095% CI 0.67-1.21
  • 08:25CESTH-ISDN meta-analysisCongress resultIn patients with HFrEF in randomised trials of hydralazine–isosorbide dinitrate, hydralazine–isosorbide dinitrate reduced clinical outcomes compared with control.
  • 08:43CESTMet-HeFTCongress resultIn 940 patients with HFrEF and diabetes or insulin resistance, metformin did not reduce death, worsening heart failure, myocardial infarction or stroke compared with placebo.HR 1.1095% CI 0.84-1.42
  • 08:53CESTMet-HeFT meta-analysisCongress resultIn patients with heart failure or ischaemic heart disease in studies of metformin, metformin did not reduce clinical outcomes compared with no metformin.
  • 09:09CESTLUMINARACongress resultIn 375 patients with chronic heart failure, AZD5462, an oral relaxin agonist improved the change in LV end-systolic volume index or systemic vascular resistance at 24 weeks compared with placebo.
  • 09:24CESTPADN-PH-LHDCongress resultIn 264 patients with pulmonary hypertension due to heart failure, pulmonary artery denervation reduced clinical worsening compared with medical therapy alone.HR 0.4995% CI 0.30-0.82
  • 09:37CESTTIME-HFCongress resultIn 1,507 patients with HFrEF at 22 hospitals in India, nurse-led, app-supported collaborative care increased days alive and out of hospital over 2 years compared with usual care.OR 1.7895% CI 1.42-2.23

Hot Line 7

11:00-12:15 CESTMain Auditorium (Hall B3)Session programme

  • 11:00CESTPOPular ACE TAVICongress resultIn 966 patients undergoing transfemoral TAVI, routine protamine after the procedure reduced death or bleeding at 30 days compared with selective protamine.
  • 11:15CESTTAVI PCICongress resultIn 986 patients with severe aortic stenosis and coronary disease, PCI after TAVI was non-inferior to PCI before TAVI for death, myocardial infarction, revascularisation, rehospitalisation or major bleeding at 1 year.22.2% vs 24.2%
  • 11:30CESTTRIC-I-HFCoreCongress resultIn 360 patients with severe tricuspid regurgitation and right heart failure, transcatheter tricuspid intervention reduced death, heart-failure hospitalisation and quality of life at 12 months compared with medical therapy alone.WR 2.4295% CI 1.76-3.33
  • 11:45CESTACASA-TAVICongress resultIn 360 patients after TAVI without an indication for anticoagulation, 12 months of a factor Xa inhibitor reduced leaflet thrombosis on CT and a safety composite at 12 months compared with aspirin.RR 0.5595% CI 0.37-0.82
  • 11:55CESTNOTION-4Congress resultIn 352 patients after TAVI without an indication for anticoagulation, 3 months of a DOAC, then antiplatelet therapy did not reduce leaflet thrombosis on CT at 1 year compared with antiplatelet therapy alone.28.3% vs 32.2%

5th Universal Definition of Myocardial Infarction (ESC, ACC, AHA, and WHF)

13:45-15:00 CESTMain Auditorium (Hall B3)Session programme

Hot Line 8

16:15-17:15 CESTMain Auditorium (Hall B3)Session programme

  • 16:15CESTAFFIRMOCongress resultIn 1,260 older patients with atrial fibrillation and multimorbidity, app-supported integrated care on the ABC pathway did not reduce unplanned hospitalisation at 12 months compared with usual care.OR 0.9595% CI 0.61-1.49
  • 16:30CESTPVI-SHAM-AFCoreCongress resultIn 262 patients with symptomatic atrial fibrillation, pulmonary vein isolation did not improve AF-specific quality of life at 6 months compared with a sham procedure.
  • 16:45CESTNEXAFCongress resultIn 295 inactive adults with non-permanent atrial fibrillation, a 12-month supervised-then-home exercise programme reduced AF burden and AF-specific quality of life at 12 months compared with usual care.3.9% vs 7.1%
  • 17:00CESTIDEAL-AFCongress resultIn 209 patients with persistent atrial fibrillation and low-voltage areas, pulmonary vein isolation plus individualised low-voltage ablation increased freedom from atrial arrhythmia at 12 months compared with pulmonary vein isolation alone.OR 3.5095% CI 1.98-6.20

Hot Line 9

17:30-18:30 CESTMain Auditorium (Hall B3)Session programme

  • 17:30CESTSHASTA-3/4Congress resultIn 757 patients with severe hypertriglyceridaemia, plozasiran every 3 months reduced the change in fasting triglycerides at 12 months compared with placebo.
  • 17:45CESTCRHCPCoreCongress resultIn 33,995 rural Chinese adults with hypertension, village-doctor-led intensive blood-pressure control reduced all-cause dementia compared with usual care.RR 0.8595% CI 0.78-0.91
  • 18:00CESTBPLTTC IPD meta-analysisCoreCongress resultIn 357,440 participants in 51 randomised blood-pressure trials, blood-pressure-lowering treatment reduced major cardiovascular events across the full spectrum of predicted risk compared with placebo or less intensive treatment.
  • 18:15CESTECLIPSE-CKDCongress resultIn 640 adults with hypertension and stage G2–G3a chronic kidney disease, a potassium-enriched salt substitute reduced systolic blood pressure at 3 months compared with regular salt.

Monday 31 August

Hot Line 10

08:15-09:30 CESTMain Auditorium (Hall B3)Session programme

  • 08:15CESTASPIREDCoreCongress resultIn 2,233 emergency patients with unexplained syncope, immediate 14-day patch ECG monitoring did not reduce self-reported syncope episodes at 1 year compared with standard care.
  • 08:30CESTDANISH-CRTCoreCongress resultIn 1,000 patients with heart failure and bundle branch block receiving CRT, electrically targeted LV lead placement did not reduce death or unplanned heart-failure hospitalisation compared with conventional lead placement.HR 1.1095% CI 0.86-1.39
  • 08:40CESTSyncAV PMTCongress resultIn 1,288 CRT recipients with left bundle branch block, dynamic AV-delay optimisation did not reduce the reduction in LV end-systolic volume at 12 months compared with a fixed AV delay.
  • 09:00CESTSyncope-StopperCongress resultIn 200 older adults with high-risk unexplained syncope, upfront pacemaker implantation reduced cardiovascular death, recurrent syncope, bradycardia or device complications at 12 months compared with standard monitoring.HR 0.4995% CI 0.27-0.87
  • 09:15CESTHIS Alternative IICongress resultIn 148 patients with HFrEF and left bundle branch block, conduction-system pacing was non-inferior to biventricular pacing for the change in LV end-systolic volume at 6 months.

2026 ESC Guidelines on Cardiac Rehabilitation

11:15-12:15 CESTMain Auditorium (Hall B3)Session programme

Hot Line 11

13:00-14:00 CESTMain Auditorium (Hall B3)Session programme

  • 13:00CESTEVAOLDCongress resultIn 587 patients aged 80 years or over with NSTEMI, a selective invasive strategy guided by stress imaging was not non-inferior to routine invasive management for death, myocardial infarction or stroke at 12 months.HR 1.2295% CI 0.86-1.72
  • 13:15CESTISOLEDSCongress resultIn 664 patients undergoing PCI of a distal left main bifurcation, OCT guidance was non-inferior to IVUS guidance for target lesion failure at 12 months.HR 0.9095% CI 0.59-1.36
  • 13:30CESTCorCalCongress resultIn 5,772 statin-naïve adults in primary prevention, coronary calcium score-guided statin therapy was not non-inferior to risk score-guided statin therapy for major adverse cardiovascular events.HR 0.9995% CI 0.71-1.38
  • 13:45CESTCoCAPCongress resultIn 360 patients after CABG for an acute coronary syndrome, dual antiplatelet therapy with ticagrelor was compared with aspirin alone on graft patency on CT angiography at 12–36 months.83.3% vs 81.6%

Hot Line 12

14:15-15:15 CESTMain Auditorium (Hall B3)Session programme

  • 14:15CESTDISCOCongress resultIn 1,003 comatose survivors of cardiac arrest without ST-elevation, immediate coronary angiography did not improve survival at 30 days compared with delayed, selective angiography.HR 0.9595% CI 0.74-1.21
  • 14:23CESTOHCA-CAG meta-analysisCongress resultIn patients resuscitated from cardiac arrest without ST-elevation in randomised trials of angiography timing, early coronary angiography did not improve clinical outcomes compared with delayed or selective angiography.
  • 14:36CESTHeartRunnerCongress resultIn 2,114 out-of-hospital cardiac arrests, smartphone activation of citizen responders did not improve survival at 30 days compared with standard EMS response.
  • 14:49CESTPRAGUE-26CoreCongress resultIn 558 patients with intermediate–high-risk pulmonary embolism, catheter-directed thrombolysis reduced death, recurrent embolism or decompensation at 7 days compared with anticoagulation alone.RR 0.1095% CI 0.02-0.44
  • 15:02CESTLAACS-2Congress resultIn 1,500 adults undergoing open-heart surgery, concomitant surgical left atrial appendage closure did not reduce stroke or TIA over 2 years compared with leaving the appendage open.HR 0.8595% CI 0.53-1.37